Galapagos Shares Surge on $5.1 Billion Gilead Investment

The video discusses the benefits of a partnership with Gilliatt, emphasizing the acceleration of innovation and maintaining independence to foster risk-taking and novel drug development. The company plans to double its R&D efforts and expand its commercial capabilities, particularly in Europe. The discussion also highlights the potential for future biotech-pharma alliances that allow for shared resources without mergers and acquisitions.

What potential impact do you foresee on the biotech sector from US drug companies looking to European biotechs?

What models of collaboration between large pharma and biotechs are suggested in the text?